Actuate Therapeutics, Inc. (NASDAQ: ACTU), a clinical-stage biopharmaceutical company, has priced its IPO at $8.00 per share. The company is offering 2,800,000 shares, resulting in gross proceeds of $22.4 million before underwriting discounts and offering expenses. Additionally, the company has granted the underwriters a 30-day option to purchase up to 420,000 additional shares to cover over-allotments, if any.

The shares are expected to begin trading on the Nasdaq Global Market on August 13, 2024, under the symbol "ACTU." The offering is expected to close on August 14, 2024, subject to customary closing conditions.

Titan Partners Group, a division of American Capital Partners, is acting as the sole bookrunner for the offering, with Newbridge Securities Corporation serving as the co-manager.